Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 May 21;13(11):2529.
doi: 10.3390/cancers13112529.

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

Kristina V Orlova  1   2 , Evgeniy V Ledin  3 , Natalia V Zhukova  4   5 , Rashida V Orlova  4   5 , Elena V Karabina  6 , Mikhail V Volkonskiy  7 , Daniil L Stroyakovskiy  2   7 , Aleksandr N Yurchenkov  7 , Svetlana A Protsenko  2   8 , Alexey V Novik  2   8 , Ludmila V Vorotilina  9 , Fedor V Moiseenko  8   10 , Victor L Chang  11 , Aleksandr I Kazmin  12 , Svetlana A Tkachenko  13 , Sergey V Gamaunov  2   14 , David R Naskhletashvili  1 , Igor V Samoylenko  1   2 , Anastasia S Vikhrova  1 , Igor A Utyashev  2   15 , Galina Yu Kharkevich  1   2 , Natalia N Petenko  1 , Irina Zh Shubina  1   2 , Lev V Demidov  1   2
Affiliations

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)

Kristina V Orlova et al. Cancers (Basel). .

Abstract

Clinical trials of targeted therapy (TT) and immunotherapy (IT) for highly aggressive advanced melanoma have shown marked improvements in response and survival rates. However, real-world data on treatment patterns and clinical outcomes for patients with advanced BRAF V600 mutant melanoma are ultimately scarce. The study was designed as an observational retrospective chart review study, which included 382 patients with advanced BRAF V600 mutant melanoma, who received TT in a real-world setting and were not involved in clinical trials. The data were collected from twelve medical centers in Russia. The objective response rates (ORRs) to combined BRAFi plus MEKi and to BRAFi mono-therapy were 57.4% and 39.8%, respectively. The median progression-free survival (PFS) and median overall survival (OS) were 9.2 months and 22.6 months, respectively, for the combined first-line therapy; 9.4 months and 16.1 months, respectively, for the combined second-line therapy; and 7.4 months and 17.1 months, respectively, for the combined third- or higher-line therapy. Analysis of treatment patterns demonstrated the effectiveness of the combined TT with BRAF plus MEK inhibitors in patients with brain metastases, rare types of BRAF mutations, and across lines of therapy, as well as a well-tolerated and manageable safety profile.

Keywords: BRAF; MEK; chart review; cobimetinib; dabrafenib; melanoma; trametinib; vemurafenib.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Targeted therapy results according to the initial LDH levels (p = 0.0156).
Figure 2
Figure 2
Overall survival according to the mutation subtype (p = 0.0268).
Figure 3
Figure 3
Overall survival in patients who received immunotherapy with anti-PD1 agents before or after targeted therapy (p = 0.0061).
See this image and copyright information in PMC

References

    1. Yang A.S., Chapman P.B. The history and future of chemotherapy for melanoma. Hematol. Oncol. Clin. N. Am. 2009;3:583–597. doi: 10.1016/j.hoc.2009.03.006. - DOI - PMC - PubMed
    1. Del Prete S.A., Maurer L.H., O’Donnell J., Forcier R.J., LeMarbre P. Combination chemotherapy with cisplatin, carmustine, dacarbazine, and tamoxifen in metastatic melanoma. Cancer Treat. Rep. 1984;68:1403–1405. - PubMed
    1. Lattanzi S., Tosteson T., Chertoff J., Maurer L.H., O’Donnell J., LeMarbre P.J., Mott L., DelPrete S.A., Forcier R.J., Ernstoff M.S. Dacarbazine, cisplatin and carmustine, with or without tamoxifen, for metastatic melanoma: 5-year follow-up. Melanoma Res. 1995;5:365–369. doi: 10.1097/00008390-199510000-00010. - DOI - PubMed
    1. Chapman P.B., Einhorn L.H., Meyers M.L., Saxman S., Destro A.N., Panageas K.S., Begg C.B., Agarwala S.S., Schuchter L.M., Ernstoff M.S., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J. Clin. Oncol. 1999;9:2745–2751. doi: 10.1200/JCO.1999.17.9.2745. - DOI - PubMed
    1. Cybulska-Stopa B., Skoczek M., Ziobro M., Switaj T., Falkowski S., Morysiński T., Hetnał M., Cedrych I., Rutkowski P. Results of systemic treatment of cutaneous melanoma in inoperable stage III and IV. Contemp. Oncol. 2012;16:532–545. doi: 10.5114/wo.2012.32487. - DOI - PMC - PubMed